Biology subjects

Signer, R. A. J.

Publications and source records attributed to Signer, R. A. J..

3 recordsLinked to original sources

bioRxiv2025

Dynamics of Ribosomal RNA Transcription and Abundance in Normal and Leukemic Hematopoiesis

Transcription of ribosomal RNAs (rRNAs) from rDNA repeats is a critical first step of ribosome biogenesis. Often deemed a housekeeping process, its cell-type-specific regulation is largely unexplored. We profiled nascent rRNA and mature rRNAs (ribosome subunits) across mouse hematopoiesis, and observed 10-fold, cell-type-specific variation in rRNA abundance that is largely uncoupled from proliferation and translation rates. We also tested and confirmed the longstanding assumption that acute myeloid leukemia progenitors show notably higher rRNA levels than matched normal counterparts. These trends in nascent rRNA across hematopoietic contexts parallel changes in the proportion of active rDNA repeats. Absolute quantification of rRNAs unexpectedly revealed an excess of large versus small ribosomal subunits in all cells, particularly in the myeloid lineage. Finally, using an RNA Polymerase I degron system, we found that reduced rRNA transcription promotes myeloid progenitor differentiation. Collectively, our work uncovers complex dynamics and functional significance of rRNA regulation in hematopoiesis.

molecular biology↗

bioRxiv2024

The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia

Oncogenic growth places great strain and dependence on the proteostasis network. This has made proteostasis pathways attractive therapeutic targets in cancer, but efforts to drug these pathways have yielded disappointing clinical outcomes. One exception is proteasome inhibitors, which are approved for frontline treatment of multiple myeloma. However, proteasome inhibitors are largely ineffective for treatment of other cancers, including acute myeloid leukemia (AML), although reasons for these differences are unknown. Here, we determined that proteasome inhibitors are ineffective in AML due to inability to disrupt proteostasis. In response to proteasome inhibition, AML cells activated HSF1 and autophagy, two key stem cell proteostasis pathways, to prevent unfolded protein accumulation. Inactivation of HSF1 sensitized human AML cells to proteasome inhibition, marked by unfolded protein accumulation, activation of the PERK-mediated integrated stress response, severe reductions in protein synthesis, proliferation and cell survival, and significant slowing of disease progression and extension of survival in vivo. Similarly, combined autophagy and proteasome inhibition suppressed proliferation, synergistically killed AML cells, and significantly reduced AML burden and extended survival in vivo. Furthermore, autophagy and proteasome inhibition preferentially suppressed protein synthesis and induced apoptosis in primary patient AML cells, including AML stem/progenitor cells, without severely affecting normal hematopoietic stem/progenitor cells. Combined autophagy and proteasome inhibition also activated the integrated stress response, but surprisingly this occurred in a PKR-dependent manner. These studies unravel how proteostasis pathways are co-opted to promote AML growth, progression and drug resistance, and reveal that disabling the proteostasis network is a promising strategy to therapeutically target AML.

cancer biology↗

bioRxiv2020

Developmental stage-specific changes in protein synthesis differentially sensitize hematopoietic stem cells and erythroid progenitors to impaired ribosome biogenesis

Ribosomopathies encompass a collection of human genetic disorders that often arise from mutations in ribosomal proteins or ribosome biogenesis factors. Despite ubiquitous requirement of ribosomes for protein synthesis, ribosomopathies present with tissue- and cell-type-specific disorders, and blood is particularly affected. Several ribosomopathies present with congenital anemias and bone marrow failure, and accordingly, erythroid lineage cells and hematopoietic stem cells (HSCs) are preferentially impaired by ribosomal dysfunction. However, the factors that influence this cell-type-specific sensitivity are incompletely understood. Here, we show that protein synthesis rates change during HSC and erythroid progenitor ontogeny. Fetal HSCs exhibit significantly higher protein synthesis than adult HSCs. Despite protein synthesis differences, reconstituting activity of both fetal and adult HSCs is severely disrupted by a ribosomal mutation (Rpl24Bst/+). In contrast, fetal erythroid lineage progenitors exhibit significantly lower protein synthesis than their adult counterparts. Protein synthesis declines during erythroid differentiation, but the decline starts earlier in fetal differentiation than in adults. Strikingly, the Rpl24Bst/+ mutation impairs fetal, but not adult erythropoiesis, by impairing proliferation at fetal erythroid progenitor stages with the lowest protein synthesis relative to their adult counterparts. Thus, developmental and cell-type-specific changes in protein synthesis can sensitize hematopoietic cells to impaired ribosome biogenesis. Key PointsO_LIFetal HSCs synthesize much more protein per hour than young adult HSCs in vivo C_LIO_LIFetal erythroid progenitors synthesize much less protein per hour than young adult erythroid progenitors in vivo C_LIO_LIDifferences in protein synthesis dynamics distinguish fetal and adult erythroid differentiation C_LIO_LIA ribosomal mutation that reduces protein synthesis impairs fetal and adult HSCs C_LIO_LIReduced protein synthesis impairs fetal but not adult erythroid progenitors C_LI

developmental biology↗